Skip to content

Prospective study to evaluate trained immunity in kidney transplantation

Prospective study to evaluate trained immunity in kidney transplantation - PROTEKT

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON53183
Enrollment
100
Registered
2023-05-15
Start date
2023-12-12
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

kidney transplantation, graft survival

Interventions

Not applicable.

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Kidney transplant recipient Age 18 - 80 years

Exclusion criteria

Exclusion criteria: No informed consent Infection in the past four weeks

Design outcomes

Primary

MeasureTime frame
1. The trained immunity profile of monocytes from renal transplant patients. Before, one week after, and three months after renal transplantation, blood is drawn from patients and circulating monocytes are isolated to examine the activity, transcriptome, and epigenome of these monocytes. 2. The association between trained immunity and renal transplant survival. The association between the trained immunity profile as measured in (1) and graft survival in the first two years after transplantation is investigated.

Secondary

MeasureTime frame
1. The association between trained immunity and inflammation and tissue damage. The association between the trained immunity profile as measured in (1) and markers for tissue damage and systemic inflammation is investigated. 2. The association between trained immunity and the concentration of immunosuppressive drugs in the blood of patients. 3. The association between trained immunity and the amount of white blood cells and subsets of white blood cells.

Countries

Netherlands

Contacts

Public ContactR Duivenvoorden

Radboud Universitair Medisch Centrum

raphael.duivenvoorden@radboudumc.nl0243614761

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)